Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Nov 12, 2019 · 10-Q · 43 days after period end · 0001213900-19-022937
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Net Income | -$6.60M | -$6.15M | -$6.32M | -$6.60M |
| EPS Diluted | -$1.21 | -$0.06 | -$0.09 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end
